The Lancet Oncology
短名 | Lancet. Oncol. |
Journal Impact | 41.73 |
国际分区 | ONCOLOGY(Q1) |
期刊索引 | SCI Q1中科院 1 区 |
ISSN | 1470-2045, 1474-5488 |
h-index | 408 |
国内分区 | 医学(1区)医学肿瘤学(1区) |
Top期刊 | 是 |
《柳叶刀肿瘤学》发表关于任何与肿瘤学相关主题的有趣且内容丰富的评论,并考虑任何倡导改变或阐明肿瘤学临床实践的原创研究贡献。手稿必须完全是作者的作品,之前不得在其他地方发表过,并且不得被其他期刊考虑。所有论文的撰写都应使期刊的读者在广泛的专业和国家中都能清楚地理解。
期刊主页投稿网址涉及主题 | 医学生物内科学遗传学化学癌症生物化学肿瘤科政治学法学病理梅德林外科 |
出版信息 | 出版商: Elsevier Ltd,出版周期: Monthly,期刊类型: journal |
基本数据 | 创刊年份: 2000,原创研究文献占比: 80.00%,自引率:1.20%, Gold OA占比: 18.31% |
平均审稿周期 | 网友分享经验:一般,3-8周 |
平均录用比例 | 网友分享经验:极难 |
期刊引文格式
这些示例是对学术期刊文章的引用,以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章,因此这些字段是可选的。有些电子期刊不提供页面范围,而是列出文章标识符。在这种情况下,使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用,以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial
2024-9-1
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial
2024-9-1
Rising costs of cancer medicines
2024-9-1
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup
2024-9-1
Improving individualised therapies in localised gastro-oesophageal adenocarcinoma
2024-9-1
Defining the quality of interdisciplinary care for patients with brain metastases: modified Delphi panel recommendations
2024-9-1
Enhancing cardiovascular disease risk management in childhood cancer survivors
2024-9-1
Correction to Lancet Oncol 2023; 24: 733–43
2024-9-1
Treatment of Richter transformation—immunotherapy to the rescue?
2024-9-1
The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect group
2024-9-1
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
2024-9-1
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
2024-9-1
New immigration laws could undermine cancer research in the UK
2024-9-1
Poor progress on reducing alcohol consumption in Europe
2024-9-1
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study
2024-9-1
European Commission approval for Dutch investment in radiopharmaceuticals
2024-9-1
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study
2024-9-1
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
2024-9-1
Contextualising legal and ethical conundrums of artificial intelligence in oncology
2024-9-1
Enhancing equity and long-term impact assessments in radiotherapy environmental studies
2024-9-1
Enhancing cardiovascular disease risk management in childhood cancer survivors
2024-9-1
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial
2024-9-1
Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?
2024-9-1
New developments in tobacco control measures in Europe
2024-9-1
Radiation oncology: a call for papers for ESTRO 2025
2024-9-1
Petition to end travel insurance discrimination against people with cancer
2024-9-1
Multimodality imaging of a large incidental papillary fibroelastoma
2024-9-1
Enhancing equity and long-term impact assessments in radiotherapy environmental studies
2024-9-1
Legacies of conflict and humanitarian crises on cancer care
2024-8-27
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
2024-8-27
Translating the theranostic concept to neuro-oncology: disrupting barriers
2024-8-27
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
2024-8-2
Disappointment facing patients with breast cancer as trastuzumab deruxtecan too expensive for NHS
2024-8-1
Ending financial discrimination for cancer survivors: embedding the Right to be Forgotten in legislation across Europe
2024-8-1
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial
2024-8-1
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial
2024-8-1
Who does not benefit from whole-breast radiotherapy and how to find them?
2024-8-1
Imatinib in advanced GIST: if it's working, don’t stop a good thing
2024-8-1
Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE
2024-8-1
A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care
2024-8-1
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
2024-8-1
Peru advances towards universal health care for patients with cancer
2024-8-1
Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial
2024-8-1
Time to abandon axillary lymph node dissection in early-stage breast cancer
2024-8-1
The UK needs to be a leader, not a lagger, in the global cancer effort
2024-8-1
Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis
2024-8-1
Measuring success of adjuvant treatment for patients with melanoma
2024-8-1
Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study
2024-8-1
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
2024-8-1
Dose selection of novel anticancer drugs: exposing the gap between selected and required doses
2024-8-1
帮你贴心管理全部的文献
研飞ivySCI,高效的论文管理
投稿经验分享
分享我的经验,帮你走得更远